RecruitingPHASE1, PHASE2NCT04577014

Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma

Studying Soft tissue sarcoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Memorial Sloan Kettering Cancer Center
Principal Investigator
Sandra D'Angelo, MD
Memorial Sloan Kettering Cancer Center
Intervention
Retifanlimab(drug)
Enrollment
98 target
Eligibility
18 years · All sexes
Timeline
20202026

Study locations (1)

Collaborators

Incyte Corporation

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04577014 on ClinicalTrials.gov

Other trials for Soft tissue sarcoma

Additional recruiting or active studies for the same condition.

See all trials for Soft tissue sarcoma

← Back to all trials